FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc.

Although sometimes portrayed in film and television as simply "falling asleep without warning," the reality of narcolepsy is ...

Axsome Therapeutics AXSM announced that the FDA has accepted the company’s new drug application (NDA) seeking approval for ...

The FDA accepted the NDA for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy, setting a PDUFA target action date of May 1, 2027.

Add Yahoo as a preferred source to see more of our stories on Google. Common symptoms of narcolepsy, including excessive daytime sleepiness, cataplexy (sudden loss of motor strength and tone), ...

Axsome Therapeutics (AXSM) stock gains as the FDA accepts the company's marketing application for its narcolepsy therapy ...

Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information and tools designed to improve your well-being. Matthew Horsnell began ...

Alkermes has released long term data for its OX2R agonist which could face two other drugs of the same mechanism of action on ...

Narcolepsy is often mistaken for stress or laziness, but this rare disorder stems from a brain chemical deficiency doctors can now treat. Here's what to know.

The clinical manifestations of symptoms experienced by children and adolescents with narcolepsy can differ from those seen in adults, presenting barriers to a timely diagnosis. The clinical ...

What do you know about narcolepsy? As a rare sleep disorder, you might not have heard much about it, or if you have, your perception may have been formed by the limited portrayals in media. Several ...

Narcolepsy is a neurological disorder that is characterized by excessive daytime sleepiness and cataplexy—a loss of muscle tone generally triggered by certain strong emotions with sudden onset. The ...